Phase 1 Lymphoblastic Lymphoma Clinical Trials
25 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 25 trials
Recruiting
Phase 1
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Lymphoblastic LymphomaAcute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc24 enrolled4 locationsNCT07586618
Recruiting
Phase 1Phase 2
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
B-cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD115 enrolled1 locationNCT05480449
Recruiting
Phase 1
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-non-Hodgkin Lymphoma
Baylor College of Medicine27 enrolled2 locationsNCT07220993
Recruiting
Phase 1Phase 2
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 1
Universal 4SCAR7U Targeting CD7-positive Malignancies
Acute Myeloid LeukemiaNK-Cell LymphomaT-cell Acute Lymphoblastic Leukemia+1 more
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT05995028
Recruiting
Phase 1
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+12 more
Ohio State University Comprehensive Cancer Center24 enrolled1 locationNCT07166419
Recruiting
Phase 1
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic Lymphoma
New York Medical College30 enrolled16 locationsNCT04972942
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2
Co-administration of CART22-65s and huCART19 for B-ALL
B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD93 enrolled1 locationNCT05674175
Recruiting
Phase 1
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+9 more
City of Hope Medical Center46 enrolled3 locationsNCT07020533
Recruiting
Phase 1Phase 2
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
Acute LeukemiaLymphoblastic LymphomaLymphoblastic Leukemia
University of Chicago15 enrolled2 locationsNCT06207123
Recruiting
Phase 1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Acute Lymphoblastic Leukemia, in RelapseAcute Leukemia of Ambiguous LineageAcute Lymphoblastic Leukemia With Failed Remission+8 more
Andrew E. Place, MD30 enrolled5 locationsNCT05292664
Recruiting
Phase 1
Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
T-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
University College, London24 enrolled1 locationNCT07300683
Recruiting
Phase 1Phase 2
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Bambino Gesù Hospital and Research Institute26 enrolled1 locationNCT06064903
Recruiting
Phase 1
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-non-Hodgkin Lymphoma
Baylor College of Medicine27 enrolled2 locationsNCT03690011
Recruiting
Phase 1Phase 2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05751044
Recruiting
Phase 1Phase 2
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled36 locationsNCT05658640
Recruiting
Phase 1Phase 2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05745714
Recruiting
Phase 1
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-non-Hodgkin Lymphoma
Baylor College of Medicine54 enrolled2 locationsNCT03081910
Recruiting
Phase 1Phase 2
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
T-lymphoblastic LymphomaRecurrent T Acute Lymphoblastic LeukemiaRefractory T Acute Lymphoblastic Leukemia+1 more
SWOG Cancer Research Network67 enrolled163 locationsNCT04315324